Currently out of the existing stock ratings of Sudan Loganathan, 41 are a BUY (78.85%), 11 are a HOLD (21.15%).

Sudan Loganathan

Work Performance Price Targets & Ratings Chart

Analyst Sudan Loganathan, currently employed at STEPHENS, carries an average stock price target met ratio of 17.04% that have a potential upside of 24.75% achieved within 38 days.

Sudan Loganathan’s has documented 104 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARVN, Arvinas at 03-Jun-2026.

Wall Street Analyst Sudan Loganathan

Analyst best performing recommendations are on SNSE (SENSEI BIOTHERAPEUTICS).
The best stock recommendation documented was for SNSE (SENSEI BIOTHERAPEUTICS) at 6/30/2025. The price target of $35 was fulfilled within 239 days with a profit of $26.42 (307.93%) receiving and performance score of 12.88.

Average potential price target upside

of $17.75 (31.71%) on KYMR (KYMERA THERAPEUTICS).

ARVN Arvinas ADCT ADC Therapeutics SA ATNM Actinium Pharmaceuticals BCYC Bicycle Therapeutics Ltd BPMC Blueprint Medicines Corp CADL Candel Therapeutics CCCC C4 Therapeutics CPRX Catalyst Pharmaceuticals DCTH Delcath Systems EXEL Exelixis IDYA Ideaya Biosciences IMNM Immunome KYMR Kymera Therapeutics NRIX Nurix Therapeutics PYXS Pyxis Oncology SNSE Sensei Biotherapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sudan Loganathan (STEPHENS)